495 Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study

Paul, Stéphane; Tedesco, Émilie Del; Marotte, Hubert; Clavel, Léa; Phelip, Jean Marc; Peyrin–Biroulet, Laurent; Roblin, Xavier

doi:10.1016/s0016-5085(13)60339-x

Cited by 64 publications

(96 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As summarized in Figure 1, in current practice, the dosage of the fecal calprotectin has two primary interests: -To differentiate organic from functional intestinal diseases, both in adult and children; -To monitor IBD therapy and predict relapses [74,75].…”

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Manceau

Chicha-Cattoir²,

Puy

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are chronic diseases that result from the inflammation of the intestinal wall, suspected in any patient presenting with intestinal symptoms. Until recently, the diagnosis was mainly based on both clinical and endoscopic arguments. The use of an easy, fast, reliable, non-invasive, and inexpensive biological assay is mandatory not only in diagnosis but also in evolutionary and therapeutic monitoring. To date, the fecal calprotectin is the most documented in this perspective. This marker allows the discrimination between functional and organic bowel processes with good performance. The determination of the fecal calprotectin level contributes to the evaluation of the degree of disease activity and to monitoring of therapeutic response.

show abstract

Section: Discussionmentioning

confidence: 99%

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Manceau

Chicha-Cattoir²,

Puy

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…In conclusion, in this study we provided evidence that BAs impair the ion transport accelerates drug clearance leading to subtherapeutic drug concentrations [80].…”

Section: The Role Of Human Colonic Epithelial Ion Transporters In Bilsupporting

confidence: 53%

Investigation of the pathomechanism of diarrhoea-related diseases

Pallagi-Kunstár¹

View full text Add to dashboard Cite

“…Paul and colleagues showed that an increase of infliximab level by more than 0.5 ug/ml was associated with increased mucosal healing by a likelihood ratio of 2.02 [Paul et al 2013]. In addition, a retrospective study of patients with IBD by Afif and colleagues showed that consideration of both the infliximab level and anti-infliximab antibody level can help guide an optimal change in therapy [Afif et al 2010].…”

Section: Change Biologic Drug Dosingmentioning

confidence: 99%

Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis

Sofia

Rubin

2016

Therap Adv Gastroenterol

View full text Add to dashboard Cite

As biologic-based medication options for ulcerative colitis expand, our understanding of their optimal use in clinical practice is advancing as well. The appropriate use of combination therapy with immunomodulators can reduce the immunogenicity of biologic agents and raise serum drug levels of the biologic. A treat-to-target strategy with objective assessments of disease activity clearly defines the goals of biologic drug treatment. Mucosal healing is an evolving treatment goal and is associated with long-term remission and reduced incidence of colectomy. Furthermore, regular reassessments and therapeutic drug monitoring can allow clinicians to make evidence-based changes in therapy. Biologic drug deescalation or re-initiation are less well developed topics, but are emerging areas of study. We review the evidence underlying these advances and a modern approach to the use of biologic therapy in ulcerative colitis.

show abstract

495 Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study

Cited by 64 publications

References 0 publications

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Investigation of the pathomechanism of diarrhoea-related diseases

Current approaches for optimizing the benefit of biologic therapy in ulcerative colitis

Contact Info

Product

Resources

About